BCL2 and melanoma: This approach was demonstrated in melanomas, using 5′-3p-siRNA sequences specific to the anti-apoptotic gene BCL2. Delivery of this construct to cells potently stimulated IFN production and NK activation, while enhancing tumor cell killing through Bcl-2 ablation [34].